Palo Alto, Calif. – September 12, 2017 – Mammoth Diagnostics today announced that it will purchase oligo pools from Twist Bioscience to develop a new class of sequence-based diagnostics.“Using comprehensive oligo pools from Twist Bioscience, we are able to quickly screen millions of unique sequence diagnostics, in massive parallelization,” commented Trevor Martin, CEO of Mammoth Diagnostics. “By forming this collaboration, we expect to revolutionize the diagnostics field by developing multiple fast, low cost, and easy-to-use sequence-based testing for bacterial and viral diseases, making the tests widely accessible.”Under the terms of the agreement, Twist Bioscience will manufacture oligo pools for Mammoth Diagnostics who will use the oligo pools use for assay development. Financial terms of the agreement were not disclosed.“There is a large and growing need for more accurate, efficient diagnostic tests” said Emily M. Leproust, Ph.D., CEO of Twist Bioscience. “Our oligo pools offer robust, highly accurate DNA sequences that can then be used to develop precision diagnostic tests specifically targeted to identify key infections. We believe the tests Mammoth Diagnostics is developing meet a critical market need and look forward to enabling their efforts.”

About Mammoth Diagnostics

Mammoth Diagnostics is a biotechnology company focused on the development of next generation diagnostics that leverage advances in synthetic biology and genomics. Our mission is to democratize the diagnostics space by bringing fast, low cost, and easy to use diagnostic tools to the market. By combining CRISPR technology with insights from evolutionary and synthetic biology we are confident in our ability to create a new class of diagnostic tools for both human disease and other commercial applications.